Welcome to the first European Bank for induced pluripotent Stem Cells (EBiSC)


EBiSC has been designed to address the increasing demand for quality-controlled, disease-relevant, research-grade iPSC lines, data and cell services.

EBiSC is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development.

EBiSC has established a robust, reliable supply chain from the generation of cell lines, over the specification, to internationally accepted quality criteria and their world-wide distribution to any qualified user.

EBiSC is a large European public-private partnership project coordinated by Pfizer Ltd and managed by Roslin Cells Siences Ltd. and supported jointly by the Innovative Medicines Initiative (IMI) and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Read more about the EBiSC project »